Development of PRO-140 (Leronlimab) as a treatment for COVID-19 [electronic resource] / Jacob Lalezari.
Material type:
SoundSeries: Henry Stewart talksBiomedical & life sciences collection. Interviews on Covid-19: Publisher: London : Henry Stewart Talks, 2020Description: 1 online resource (1 streaming audio file (20 min.))Subject(s): Coronavirus infections -- Treatment | COVID-19 (Disease) | Drug development | CCR5 Receptor Antagonists -- therapeutic use | Coronavirus Infections -- drug therapy | COVID-19 -- drug therapy | Drug Development | Inflammation | leronlimab | Pharmaceutical Preparations | Receptors, CCR5 | SARS-CoV-2Online resources: Click here to access online | Series Audio interview.
Title from title frames.
Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?
Access restricted to subscribers.
Mode of access: World Wide Web.